{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:53:02Z","timestamp":1791604382567,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cllc.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:45:58Z","timestamp":1786117558000},"page":"33-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prolonged Disease Control on Tepotinib in a Patient With HLA-DRB1-MET-Positive Metastatic Non\u2013small Cell Lung Cancer: The Role of RNA Sequencing and Targeted Therapy for Rare MET Rearrangements"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7365-0237","authenticated-orcid":false,"given":"Jason Y.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Kelekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-9692","authenticated-orcid":false,"given":"Mon","family":"Miyakawa-Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3338-2784","authenticated-orcid":false,"given":"Nathaniel J.","family":"Myall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2026.08.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae166","article-title":"Dramatic response to crizotinib through MET phosphorylation inhibition in rare TFG-MET fusion advanced squamous cell lung cancer","volume":"30","author":"Cheng","year":"2025","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.002_bib0002","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12967-023-03999-7","article-title":"Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer","volume":"21","author":"Sun","year":"2023","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.002_bib0003","article-title":"Targeting MET in NSCLC: an ever-expanding territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO Clin Res Rep"},{"issue":"11","key":"10.1016\/j.cllc.2026.08.002_bib0004","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1634\/theoncologist.2020-0502","article-title":"Tepotinib efficacy in a patient with non-small cell lung cancer with brain metastasis harboring an HLA-DRB1-MET gene fusion","volume":"25","author":"Blanc-Durand","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.002_bib0005","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.002_bib0006","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jtho.2023.06.020","article-title":"MET fusions in NSCLC: clinicopathologic features and response to MET inhibition","volume":"19","author":"Riedel","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2026.08.002_bib0007","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.21037\/tlcr-24-34","article-title":"A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report","volume":"13","author":"Dias E Silva","year":"2024","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"10.1016\/j.cllc.2026.08.002_bib0008","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/2159-8290.CD-20-1230","article-title":"St. Jude Cloud: a pediatric cancer genomic data-sharing ecosystem","volume":"11","author":"McLeod","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.002_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/ng.3466","article-title":"Exploring genomic alteration in pediatric cancer using ProteinPaint","volume":"48","author":"Zhou","year":"2016","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.002_bib0010","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1158\/1078-0432.CCR-17-3001","article-title":"Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients","volume":"24","author":"Plenker","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.08.002_bib0011","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lungcan.2023.01.017","article-title":"Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer","volume":"178","author":"Kang","year":"2023","journal-title":"Lung Cancer"},{"issue":"13","key":"10.1016\/j.cllc.2026.08.002_bib0012","doi-asserted-by":"crossref","first-page":"14015","DOI":"10.1002\/cam4.6047","article-title":"Molecular characterization of MET fusions from a large real-world Chinese population: a multicenter study","volume":"12","author":"Xia","year":"2023","journal-title":"Cancer Med"},{"issue":"15_suppl","key":"10.1016\/j.cllc.2026.08.002_bib0013","article-title":"MET gene fusions in non-small cell lung cancer (NSCLC) in the Chinese population: a multicenter study [abstract]","volume":"36","author":"Wang","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.08.002_bib0014","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jtho.2017.10.014","article-title":"KIF5B-MET gene rearrangement with robust antitumor activity in response to crizotinib in lung adenocarcinoma","volume":"13","author":"Cho","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2026.08.002_bib0015","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial [published correction appears in JAMA Oncol. 2023 Sep 1;9(9):1300. 10.1001\/jamaoncol.2023.2810.]","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.002_bib0016","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.cllc.2026.08.002_bib0017","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or Placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.cllc.2026.08.002_bib0018","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1002\/cncr.27637","article-title":"Driver mutations determine survival in smokers and never-smokers with stage IIIB\/IV lung adenocarcinomas","volume":"118","author":"Paik","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.cllc.2026.08.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103668","article-title":"A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)","volume":"9","author":"Kang","year":"2024","journal-title":"ESMO Open"},{"issue":"25","key":"10.1016\/j.cllc.2026.08.002_bib0020","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00117","article-title":"Dramatic response to Crizotinib in a patient with lung cancer positive for an HLA-DRB1-MET gene fusion","volume":"2017","author":"Davies","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.002_bib0022","article-title":"MET-UBE2H fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma","volume":"13","author":"Zhu","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2026.08.002_bib0023","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1093\/annonc\/mdy455","article-title":"Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing","volume":"29","author":"Zhu","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.08.002_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.727662","article-title":"A novel c-mesenchymal-epithelial transition factor intergenic fusion response to Crizotinib in a Chinese patient with lung adenocarcinoma: a case report","volume":"11","author":"Liang","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.08.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2020.05.005","article-title":"A case of HLA-DRB1-MET rearranged lung adenocarcinoma with rapid response to Crizotinib","volume":"22","author":"Kunte","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.002_bib0026","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.21037\/tcr-22-141","article-title":"Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report","volume":"11","author":"Liu","year":"2022","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.cllc.2026.08.002_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.919123","article-title":"Case report: salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin","volume":"12","author":"Lin","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2026.08.002_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.911362","article-title":"Case Report: durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D\/L861Q mutations and an acquired novel CUX1-MET fusion","volume":"12","author":"Ou","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.002_bib0029","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.12998\/wjcc.v10.i8.2529","article-title":"Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: a case report","volume":"10","author":"Liu","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.cllc.2026.08.002_bib0030","article-title":"Case report: dramatic response to crizotinib in a patient with non-small cell lung cancer positive for a novel ARL1-MET fusion","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.002_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2022.10.001","article-title":"A novel PRKAR1A::MET fusion dramatic response to crizotinib in a patient with unresectable lung cancer","volume":"24","author":"Yang","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2026.08.002_bib0032","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/OTT.S442685","article-title":"Response to savolitinib in a patient with advanced poorly differentiated lung carcinoma positive for a novel EML4-MET gene fusion","volume":"17","author":"Ouyang","year":"2024","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cllc.2026.08.002_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1370901","article-title":"Case report: acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion","volume":"14","author":"Dong","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.002_bib0034","first-page":"103","article-title":"Unveiling the uncommon: a comprehensive review and case report on targeting rare MET fusions in NSCLC","volume":"12","author":"Mu\u011flu","year":"2026","journal-title":"J Oncol Sci"},{"issue":"15","key":"10.1016\/j.cllc.2026.08.002_bib0035","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/cncr.34801","article-title":"RNA sequencing steps toward the first line","volume":"129","author":"Boyle","year":"2023","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.cllc.2026.08.002_bib0036","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3052","article-title":"RNA sequencing effectively identifies gene fusions undetected by DNA sequencing in lung adenocarcinomas [abstract]","volume":"39","author":"Zhao","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2026.08.002_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.42970","article-title":"Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer","volume":"7","author":"Owen","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.cllc.2026.08.002_bib0038","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","article-title":"Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.cllc.2026.08.002_bib0039","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1535-7163.MCT-22-0537","article-title":"The preclinical pharmacology of tepotinib-A highly selective MET inhibitor with activity in tumors harboring MET alterations","volume":"22","author":"Albers","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"15_suppl","key":"10.1016\/j.cllc.2026.08.002_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9012","article-title":"METex14 ctDNA dynamics & resistance mechanisms detected in liquid biopsy (LBx) from patients (pts) with METex14 skipping NSCLC treated with tepotinib [abstract]","volume":"39","author":"Paik","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2026.08.002_bib0041","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.jtho.2023.09.107","article-title":"OA21.06 ctDNA dynamics, prognostic markers and resistance mechanisms in Tepotinib-treated METex14 skipping NSCLC in the VISION trial","volume":"18","author":"Le","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.002_bib0042","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.1016\/j.jtho.2019.08.572","article-title":"MA09.10 Comprehensive analysis of secondary mutation as resistance mechanism to seven MET-TKIs for MET exon 14 skipping in vitro","volume":"14","author":"Fujino","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.002_bib0043","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","article-title":"Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro","volume":"14","author":"Fujino","year":"2019","journal-title":"J Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:26:32Z","timestamp":1791602792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1525730426001063"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged Disease Control on Tepotinib in a Patient With HLA-DRB1-MET-Positive Metastatic Non\u2013small Cell Lung Cancer: The Role of RNA Sequencing and Targeted Therapy for Rare MET Rearrangements","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}